Novartis Culls Pipeline As ‘Pure-Play’ Drive Progresses

Removes PD-1 Inhibitor, Adds To Radioligand Pipeline

 
• By Andrew McConaghie
  
Novartis NIBR Cambridge, MA
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Earnings

More from Business